Biomarkers in Samples From Patients With Chronic Lymphocytic Leukemia Treated on Clinical Trial ECOG-2997

NCT00899873 — Completed, 225 participants, ECOG-ACRIN Cancer Research Group

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Proposed Study of CLL Samples

RegistryNCT00899873
StatusCompleted
Study typeObservational
Enrollment225 (Actual)
SponsorECOG-ACRIN Cancer Research Group (Network); collaborators: National Cancer Institute (NCI)
ConditionsLeukemia
Interventionscytogenetic analysis, flow cytometry, fluorescence activated cell sorting, immunoenzyme technique, laboratory biomarker analysis (Genetic, other)
Datesstart 2012-04-17, primary completion 2012-07-17, completion 2012-07-17, first posted 2009-05-12, last updated 2017-05-17

Related Papers Related Patents Related Grants Related Experts
All trials for Leukemia All trials of cytogenetic analysis All trials of flow cytometry

-Summary

RATIONALE: Studying samples of cells in the laboratory from patients with cancer may help identify biomarkers related to cancer. It may also help doctors learn how patients respond to treatment.

PURPOSE: This laboratory study is analyzing samples of cells from patients with chronic lymphocytic leukemia who were treated on clinical trial ECOG-2997.

Expand all sections  ·  Collapse all

+Detailed description

OBJECTIVES:

* To analyze the expression of a variety of informative molecules using a unique high-resolution flow cytometric immunophenotyping technology in samples from patients with chronic lymphocytic leukemia enrolled in clinical trial ECOG-2997.

OUTLINE: Cell samples are analyzed for the following prognostic biomarkers: ZAP-70, phospho-Syk, phospho-GSK-3β, phospho-Akt, phospho-ZAP-70, cyclin D1, cyclin D2, p21cip1, phospho-ReIA, IkappaBα, Bax, Mcl-1, PTEN, phospho-Erk1/2, and phospho-MEK1/2. Biomarker signals are amplified using enzymatic amplification staining to obtain high resolution detection of cell-surface markers on leukemic cells. Biomarker expression levels are measured using fluorescence activated cell sorting analysis. Relationships between clinical outcomes, standard flow cytometric analysis, cytogenetic studies, and high resolution immunophenotyping will also be assessed.

+Arms and interventions

  • cytogenetic analysis (Genetic)
  • flow cytometry (Other)
  • fluorescence activated cell sorting (Other)
  • immunoenzyme technique (Other)
  • laboratory biomarker analysis (Other)

+Outcome measures

Primary outcomes

  • Correlation of biomarker analysis and correlation with outcome response [1 month]

+Eligibility

Sex: All, ages: 18 Years to 120 Years

DISEASE CHARACTERISTICS:

* Stored frozen viable cells from patients with chronic lymphocytic leukemia treated on clinical trial ECOG-2997

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* Not specified

+Investigators